Argyropoulos S V, Sandford J J, Nutt D J
Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK.
Pharmacol Ther. 2000 Dec;88(3):213-27. doi: 10.1016/s0163-7258(00)00083-8.
Benzodiazepines have been the mainstay of pharmacological treatment of anxiety over the last 4 decades. The problems associated with their use prompted the research for alternative agents that would be useful in anxiety conditions. Old classes of antidepressants, such as tricyclic antidepressants and monoamine oxidase inhibitors, showed effectiveness in some anxiety syndromes, even in areas where benzodiazepines were not very effective. Newer antidepressants, the selective serotonin-reuptake inhibitors, also appear very useful in some anxiety states, and their favourable side-effect profile has elevated them to first-line treatment tools in these conditions. However, the ideal anxiolytic does not exist. Research with other new compounds is very active, and some experimental drugs show promise for the future.
在过去40年里,苯二氮䓬类药物一直是焦虑症药物治疗的主要手段。与使用这类药物相关的问题促使人们研究可用于焦虑症治疗的替代药物。老一代抗抑郁药,如三环类抗抑郁药和单胺氧化酶抑制剂,在某些焦虑综合征中显示出有效性,甚至在苯二氮䓬类药物效果不佳的领域也是如此。新一代抗抑郁药,即选择性5-羟色胺再摄取抑制剂,在某些焦虑状态下似乎也非常有用,且其良好的副作用特征使它们在这些情况下成为一线治疗药物。然而,理想的抗焦虑药并不存在。对其他新化合物的研究非常活跃,一些实验性药物显示出未来的应用前景。